| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
ODN-M-362 specifically targets Toll-like receptor 9 (TLR9), a pattern recognition receptor expressed in endosomes of immune cells, particularly plasmacytoid dendritic cells (pDCs) and B cells. By binding to TLR9, ODN-M-362 triggers an initial innate immune response via TLR9 upregulation. This is followed by the enhancement of MamA-specific CTL (cytotoxic T lymphocyte)-dependent adaptive immune responses, resulting in a powerful and balanced adjuvant effect.
|
|---|---|
| ln Vitro |
In vitro, ODN-M-362 induces the activation and maturation of dendritic cells, leading to the production of pro-inflammatory cytokines. It has been shown to induce apoptosis in cancer cells. In immune cell cultures, it upregulates the expression of co-stimulatory molecules such as CD80 and CD86 on antigen-presenting cells. It also promotes the proliferation and differentiation of B cells and the activation of Natural Killer (NK) cells.
|
| ln Vivo |
In vivo, ODN-M-362 has been shown to exert a strong adjuvant effect. When administered with a tumor antigen, it promotes the generation of antigen-specific CTL responses that can eliminate established tumors. It demonstrates potential for use as a vaccine adjuvant for cancer therapy, where it can enhance the efficacy of cancer vaccines by breaking immune tolerance and generating robust anti-tumor immunity.
|
| Enzyme Assay |
For non-cell-based TLR9 binding assays, a standard protocol involves using a biotinylated CpG DNA ligand immobilized on a streptavidin-coated surface. Recombinant human or mouse TLR9 is incubated with the plate. ODN-M-362 is then added in a concentration range (0.1 nM - 10 microM) to compete for binding. The amount of bound TLR9 is detected using a specific antibody and an HRP-conjugated secondary antibody. The IC50 for competition is calculated.
|
| Cell Assay |
For in vitro cell assays, mouse splenocytes or human PBMCs are seeded in 96-well plates. ODN-M-362 is added at various concentrations (0.1-10 microM) and incubated for 24-48 hours. Supernatants are collected for cytokine measurement (e.g., IFN-alpha, IL-6, TNF-alpha, IP-10) by ELISA or multiplex immunoassay. Alternatively, the activation of NF-kappaB and IRF7 pathways can be measured using a reporter cell line that expresses SEAP (secreted alkaline phosphatase) upon TLR9 activation.
|
| Animal Protocol |
For in vivo animal models, a tumor vaccine model is used. Mice are injected subcutaneously with tumor cells (e.g., EG7-OVA thymoma cells). On days 3, 7, and 11 after tumor challenge, mice are vaccinated with a tumor antigen (e.g., OVA protein) mixed with ODN-M-362 (50 microg per dose) and a suitable delivery vehicle. A control group receives antigen alone. Tumor growth is monitored. Survival is recorded. Mice are euthanized when tumors exceed 2000 mm3. CTL activity is assessed by a standard chromium release assay using splenocytes from vaccinated mice.
|
| ADME/Pharmacokinetics |
ODN-M-362 is a synthetic oligonucleotide with a phosphorothioate backbone, which significantly increases its metabolic stability. This modification protects it from rapid degradation by nucleases in the serum and tissues, extending its in vivo half-life. It is typically administered locally (e.g., intramuscularly or intratumorally) to concentrate the immunostimulatory effect at the desired site. Systemic distribution does occur, which contributes to the systemic adjuvant effect but also to potential toxicity.
|
| Toxicity/Toxicokinetics |
As a potent TLR9 agonist, ODN-M-362 has the potential for mechanism-based toxicity. Overstimulation of the immune system can lead to a "cytokine release syndrome" (CRS), characterized by high fever, hypotension, and multi-organ failure. In preclinical models, high systemic doses may cause transient splenomegaly and lymphoid follicle enlargement. It may also exacerbate pre-existing autoimmune conditions. The dose and schedule must be carefully optimized to balance efficacy and toxicity.
|
| References |
|
| Additional Infomation |
ODN-M-362 is a research-grade reagent and is not an approved drug. As a Class C CpG ODN, its unique structure allows it to combine the strong pDC activation (IFN-alpha production) characteristic of Class A ODNs with the strong B cell activation (proliferation and antibody production) characteristic of Class B ODNs. This makes it particularly attractive for applications where both potent antibody responses and strong T cell responses are desired, such as in cancer immunotherapy. It is not approved for human use and is strictly for research applications.
|
| Molecular Formula |
NA MOLECULARWEIGHT
|
|---|---|
| CAS # |
934655-87-5
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~12.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
